Skip to main content
ANVS
NYSE Life Sciences

Annovis Discloses Only ~$2.8M Cash at Sept 30 — Days After NYSE Listing Deficiency Notice

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.88
Mkt Cap
$51.642M
52W Low
$0.93
52W High
$5.5
52W Position info
5.3% below low
Off High info
84% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ANVS is trading near its 52-week low of $0.93 (5.3% below the low).

Summary

Annovis preliminarily reported about $2.8 million of cash as of September 30, 2026, filed the same day stockholders approved doubling authorized shares to 140 million. With a fresh NYSE listing deficiency notice outstanding, the company has minimal runway and a newly enlarged share authorization to raise capital against.


Key Events · Earnings and Guidance · ANVS

  • Preliminary Q3 Cash of ~$2.8M

    Annovis estimates cash and cash equivalents of approximately $2.8 million as of September 30, 2026 — preliminary, unaudited and not reviewed by its auditors.

  • Runway Looks Very Thin

    The $2.8 million balance compares with $18.7 million in cash reported at the Q2 2026 update on August 14, 2026, implying roughly $15.9 million consumed in the quarter (18.7 - 2.8 = 15.9).

  • NYSE Listing Deficiency Outstanding

    The October 29, 2026 NYSE notice that Annovis fails Section 802.01B remains unresolved; the enlarged authorization does not by itself cure the market-cap shortfall.

  • 140M Authorized Shares Cleared Same Day

    Stockholders approved doubling authorized common stock from 70 million to 140 million, with the charter amendment filed in Delaware on November 4, 2026; no shares have been issued under it.


Analysis · ANVS · Life Sciences

Annovis ended the third quarter with roughly $2.8 million in cash, a preliminary figure disclosed the same day shareholders approved doubling authorized shares to 140 million. That combination is the story: the company has very little runway left, has just cleared the way to issue more stock, and is already on notice from the NYSE that its market cap has fallen below the continued-listing standard. The cash number is unaudited and subject to change, but at this level the next equity raise is a question of when, not if — and it will come at a share price near the 52-week low.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANVS was trading at $0.88 on NYSE in the Life Sciences sector, with a market capitalization of approximately $51.6M. The 52-week trading range was $0.93 to $5.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANVS - Latest Insights

ANVS
Nov 20, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.7559
Real-time Price: $0.730 info
Change: -$0.0259 (-3%) info
Market Cap: $44.117M info
ANVS
Nov 17, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.730 info
Change: -$0.070 (-9%) info
Market Cap: $44.117M info
ANVS
Nov 13, 2026, 4:24 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.940
Real-time Price: $0.730 info
Change: -$0.210 (-22%) info
Market Cap: $44.117M info
ANVS
Nov 06, 2026, 4:30 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.8799
Real-time Price: $0.730 info
Change: -$0.1499 (-17%) info
Market Cap: $44.117M info
ANVS
Nov 05, 2026, 8:05 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $0.8689
Real-time Price: $0.730 info
Change: -$0.1389 (-16%) info
Market Cap: $44.117M info